SG159389A1 - Hsa-free stabilized interferon liquid formulations - Google Patents

Hsa-free stabilized interferon liquid formulations

Info

Publication number
SG159389A1
SG159389A1 SG200705206-1A SG2007052061A SG159389A1 SG 159389 A1 SG159389 A1 SG 159389A1 SG 2007052061 A SG2007052061 A SG 2007052061A SG 159389 A1 SG159389 A1 SG 159389A1
Authority
SG
Singapore
Prior art keywords
hsa
liquid formulations
stabilized interferon
free stabilized
interferon liquid
Prior art date
Application number
SG200705206-1A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Rio Alessandra Del
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of SG159389A1 publication Critical patent/SG159389A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG200705206-1A 2003-05-01 2004-04-29 Hsa-free stabilized interferon liquid formulations SG159389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03101210 2003-05-01
US53016903P 2003-12-17 2003-12-17
PCT/EP2004/004806 WO2004096263A2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
SG159389A1 true SG159389A1 (en) 2010-03-30

Family

ID=36908159

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200705206-1A SG159389A1 (en) 2003-05-01 2004-04-29 Hsa-free stabilized interferon liquid formulations

Country Status (29)

Country Link
US (1) US8309069B2 (ja)
EP (1) EP1617861B1 (ja)
JP (2) JP4870550B2 (ja)
KR (1) KR101116058B1 (ja)
CN (1) CN1816347B (ja)
AR (1) AR044147A1 (ja)
AU (2) AU2004233603B2 (ja)
BR (1) BRPI0410488B8 (ja)
CA (1) CA2521560A1 (ja)
DK (1) DK1617861T3 (ja)
EA (2) EA200800327A1 (ja)
ES (1) ES2417061T3 (ja)
HK (1) HK1088847A1 (ja)
HR (1) HRP20130512T1 (ja)
IL (1) IL171709A (ja)
ME (1) ME00404B (ja)
MX (1) MXPA05011718A (ja)
MY (1) MY151121A (ja)
NO (1) NO335674B1 (ja)
NZ (2) NZ542912A (ja)
PL (1) PL1617861T3 (ja)
PT (1) PT1617861E (ja)
RS (1) RS52869B (ja)
SG (1) SG159389A1 (ja)
SI (1) SI1617861T1 (ja)
TW (1) TWI272948B (ja)
UA (2) UA80331C2 (ja)
WO (1) WO2004096263A2 (ja)
ZA (2) ZA200508124B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526032T1 (de) * 2003-12-11 2011-10-15 Ares Trading Sa Stabilisierte flüssige interferon-formulierungen
CN1984673A (zh) * 2004-05-17 2007-06-20 阿雷斯贸易股份有限公司 干扰素水凝胶制剂
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
UA95461C2 (en) * 2005-09-14 2011-08-10 Арес Трейдинг С.А. Method for quantitative determination of poloxamers
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
PL2134353T3 (pl) * 2007-03-30 2017-06-30 Helix Biopharma Corp. Dwufazowa kompozycja pęcherzyków lipidowych i sposób leczenia dysplazji szyjki macicy przez podawanie dopochwowe
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
RS52417B (en) 2007-12-20 2013-02-28 Merck Serono S.A. PEG-INTERFERON-BETA FORMULATIONS
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224940A1 (de) * 1997-09-23 2002-07-24 Rentschler Biotechnologie GmbH & Co. KG Flüssige Interferon-Beta Formulierungen
WO2002080976A2 (en) * 2001-04-09 2002-10-17 Chiron Corporation Hsa-free formulations of interferon-beta
WO2003006053A1 (en) * 2001-07-09 2003-01-23 Schering Aktiengesellschaft HUMAN INTERFERON-β FORMULATIONS

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
JP4878664B2 (ja) 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6299869B1 (en) * 1997-12-08 2001-10-09 Genentech, Inc. Human interferon-epsilon: a type I interferon
ES2224649T3 (es) 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
CA2331816C (en) * 1998-05-11 2010-11-16 Basf Aktiengesellschaft Method for producing isoxazoline-3-yl-acyl benzene
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
ATE526032T1 (de) 2003-12-11 2011-10-15 Ares Trading Sa Stabilisierte flüssige interferon-formulierungen
CN1984673A (zh) 2004-05-17 2007-06-20 阿雷斯贸易股份有限公司 干扰素水凝胶制剂
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224940A1 (de) * 1997-09-23 2002-07-24 Rentschler Biotechnologie GmbH & Co. KG Flüssige Interferon-Beta Formulierungen
WO2002080976A2 (en) * 2001-04-09 2002-10-17 Chiron Corporation Hsa-free formulations of interferon-beta
WO2003006053A1 (en) * 2001-07-09 2003-01-23 Schering Aktiengesellschaft HUMAN INTERFERON-β FORMULATIONS

Also Published As

Publication number Publication date
AU2004233603A1 (en) 2004-11-11
PT1617861E (pt) 2013-08-28
ZA200508124B (en) 2009-02-25
TWI272948B (en) 2007-02-11
TW200503754A (en) 2005-02-01
EP1617861A2 (en) 2006-01-25
ES2417061T3 (es) 2013-08-05
AU2009201261A1 (en) 2009-04-23
JP2011225599A (ja) 2011-11-10
BRPI0410488B8 (pt) 2021-09-08
JP4870550B2 (ja) 2012-02-08
NZ542912A (en) 2008-04-30
WO2004096263A2 (en) 2004-11-11
CN1816347B (zh) 2010-07-21
MY151121A (en) 2014-04-30
JP5346065B2 (ja) 2013-11-20
CN1816347A (zh) 2006-08-09
HK1088847A1 (en) 2006-11-17
UA94032C2 (ru) 2011-04-11
ME00404B (me) 2011-10-10
EP1617861B1 (en) 2013-05-29
US20070059285A1 (en) 2007-03-15
NO20055666L (no) 2005-11-30
BRPI0410488A (pt) 2006-06-13
ZA200708484B (en) 2008-10-29
PL1617861T3 (pl) 2013-10-31
MXPA05011718A (es) 2006-01-23
EA009995B1 (ru) 2008-06-30
EA200501699A1 (ru) 2006-06-30
RS20050821A (en) 2007-12-31
MEP60408A (en) 2011-05-10
KR101116058B1 (ko) 2012-04-12
CA2521560A1 (en) 2004-11-11
EA200800327A1 (ru) 2008-10-30
NO335674B1 (no) 2015-01-19
IL171709A (en) 2016-03-31
AR044147A1 (es) 2005-08-24
SI1617861T1 (sl) 2013-09-30
RS52869B (sr) 2013-12-31
JP2006525280A (ja) 2006-11-09
AU2004233603B2 (en) 2009-02-26
HRP20130512T1 (hr) 2013-07-31
NZ566625A (en) 2010-02-26
WO2004096263A3 (en) 2004-12-02
KR20060011976A (ko) 2006-02-06
DK1617861T3 (da) 2013-07-29
US8309069B2 (en) 2012-11-13
BRPI0410488B1 (pt) 2021-06-22
UA80331C2 (en) 2007-09-10

Similar Documents

Publication Publication Date Title
SG159389A1 (en) Hsa-free stabilized interferon liquid formulations
NO20065860L (no) Stabiliserte flytende interferonformuleringer
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
DK1412384T3 (da) Stabil formulering af modificeret GLP-1
AU2003213020A1 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
AU2002327097A1 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
RS52417B (en) PEG-INTERFERON-BETA FORMULATIONS
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ZA200403803B (en) Selective targeting of apoptotic cells.
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
DK1409021T3 (da) Formulering omfattende fulvestrant
AR034749A1 (es) Formulaciones de interferon beta humano
ATE228300T1 (de) Wirkstoffhaltige polyetherblockamide
IL149899A0 (en) MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION HCl AS ACTIVE SUBSTANCE
AU2002356739A1 (en) Antiglaucomatous agent and use thereof
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη
IT1254453B (it) Composizioni farmaceutiche per uso orale a base di glutatione ridotto